Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15 year follow up of a phase II study from MD Anderson Cancer Center

BACKGROUND: Mantle cell lymphoma remains an aggressive and incurable malignancy. Intensive chemotherapy regimens containing cytarabine have substantially improved remission durability and overall survival, particularly in younger adults. However, there have been no long-term follow-up results for pa...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Haematol
Prif Awduron: Chihara, Dai, Cheah, Chan Yoon, Westin, Jason R., Fayad, Luis E., Rodriguez, Maria Alma, Hagemeister, Fredrick B., Pro, Barbara, McLaughlin, Peter, Younes, Anas, Samaniego, Felipe, Goy, Andre, Cabanillas, Fernando, Kantarjian, Hagop, Kwak, Larry W., Wang, Michael L., Romaguera, Jorge E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5471614/
https://ncbi.nlm.nih.gov/pubmed/26648336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13796
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg